^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion + EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Int J Cancer
    Title:

    Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation

    Published date:
    09/24/2021
    Excerpt:
    Exon 20 insertion and dT790MHAF patients demonstrated a significantly shortened PFS (2.6 and 4.1 months) compared to EGFR common mutation, dT790MLAF and other uncommon mutation patients (15.1, 27.0 and 18.4 months; p= 3x10-8 )….Afatinib-treated NSCLC patients presented an EGFR genotype-specific pattern of disease progression and outcome.
    DOI:
    10.1002/ijc.33821